Sorry for the duplicate posts, but I wanted to mention that SZYM was up 6% on pretty reasonable volume Friday, and was up a further 6% after hours. I don't follow "Mad Money" but I was trying to source this move and found out that Friday night Jim Cramer covered spec stocks using SZYM as an example:

Analyzing a Speculative Stock

For "Speculation Friday," Cramer dove into the stock of Solazyme and offered viewers a look into the step-by-step process he uses to evaluate a speculative stock.

Step one, what does it do? Cramer said that Solazyme is developing an industrial biotech platform that uses algae to turn plants into specialty oils. The company has almost no sales and even fewer profits, but does have a ton of potential applications, including everything from personal care products to bio-fuel for aviation.

Step two, bloodlines. Cramer said Solazyme was founded in 2003 but only came public in 2011. It's cofounders include a science guy and a business guy, and its CFO is a finance guy, completing the needed trifecta. The IPO had great underwriters in Morgan Stanley and Goldman Sachs.

Step three, potential upside. Solazyme has created a host of valuable partnerships, including with Bunge (BG), an agricultural giant, Chevron (CVX), makers of diesel fuel, the U.S. Navy, which needs bio-fuels, and Sephora, makers of skin care and cosmetics.

Step four, addressable market. Cramer said the market opportunities for Solazyme are gigantic, if the company can actually ramp up production of its technologies in any one of its many market opportunities. The company's first plant is expected to come online in mid-2013.

Step five, the risks. Cramer said the company has enough capital to fund itself, with $243 million in cash, a solid balance sheet and the ability to borrow more if it needs to. What about competition? Solazyme smarter partnered with just about everyone who would potentially want to compete with it. Cramer said once again that the only real risk is if the company can execute on its plans.

Step six, your personal risk tolerance. Cramer said with no real catalyst until 2013, the decision to own Solazyme should only be made if investors feel it fits their personal risk tolerances. But by using these six steps, he said investors can easily make a smart decision on this, or any other, speculative stock they come across.

YYMV,

TAC